in those systems using cannabinoid receptors should be discovered in
schizophrenia.
It is now known that anandamide("the" natural endogenous substance
acting on cannabinoid receptors)is,like 9-THC,an agonist at those
receptors and that stimultation of these receptors can lead to
decreased glutamate neurotransmission.
Anandamide might,possibly,be involved in schizophrenia via glutamate
mediation.
One sparrow does not make spring!
Still:this report is intriguing.If confirmed it may,perhaps,be that
some atypical anti-psychotics
act by modulating glutamate neurotransmission throuh modulation of
cannabinoid receptors.
According to my theory anandamide neurotransmission should be
"increased" in schizophrenics.
It will be interesting to see if atypical neuroleptics like clozapine
and olanzapine have any activity on cannabinoid receptors.
The effects of MDMA on these receptors should also be studied,in case!
The future will tell the tale...
Cheers,
Claude
See:http://dog.net.uk/claude
